Compare PEN & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PEN | CYTK |
|---|---|---|
| Founded | 2004 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8B | 10.4B |
| IPO Year | 2015 | 2004 |
| Metric | PEN | CYTK |
|---|---|---|
| Price | $319.34 | $69.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 19 |
| Target Price | ★ $360.14 | $89.26 |
| AVG Volume (30 Days) | 379.6K | ★ 1.7M |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1155.56 | N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $1,403,665,000.00 | $13,368,000.00 |
| Revenue This Year | $14.34 | $7.37 |
| Revenue Next Year | $13.71 | $310.19 |
| P/E Ratio | $389.44 | ★ N/A |
| Revenue Growth | ★ 17.50 | N/A |
| 52 Week Low | $221.26 | $31.99 |
| 52 Week High | $362.41 | $80.20 |
| Indicator | PEN | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 38.05 | 45.21 |
| Support Level | $317.81 | $59.07 |
| Resistance Level | $322.24 | $70.69 |
| Average True Range (ATR) | 2.48 | 2.87 |
| MACD | 0.04 | -1.15 |
| Stochastic Oscillator | 14.25 | 25.26 |
Penumbra Inc is a thrombectomy company focused on developing technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism (including pulmonary embolism), and acute limb ischemia. Its portfolio includes Computer-Assisted Vacuum Thrombectomy (CAVT), which is designed to remove blood clots throughout the body. The company offers products such as the Artemis Neuro Evacuation Device (used for surgical removal of fluid and tissue from the ventricles and cerebrum), Indigo System, Penumbra System Reperfusion Catheter, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and ACE Reperfusion Catheters, among others. The company generates maximum revenue from the sale of its products in the United States, followed by international markets.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.